We hypothesize that factors beyond phosphate, such as CKD-related cytokines, angiotensin II or transforming growth factor-beta (TGF-β), may be responsible for stimulating FHL2 in VSMCs in vivo [27]. This evidence concerns the gene AGT and chronic kidney disease.